In spite of over thirty years of effort, the prognosis for patients afflicted with malignant gliomas remains dismal. It is the purpose of this Brain Cancer SPORE to have a positive impact on this unacceptable situation by translating the laboratory-based efforts of five groups of scientists into clinical protocols that address the needs for more effective treatments. The themes that will be investigated in this SPORE include: Pathogenesis, Anti-Invasion Strategies, Glioma-Host Interactions, Viral and Gene Therapy, and Anti-Angiogenesis Strategies. Five research projects are proposed, each of which has a translational component that has or is expected to lead to a clinical research protocol. These include: 1) """"""""The role of Human Cytomegalovirus in Human Malignant Glioma Pathogenesis"""""""" which will examine an intriguing finding that suggests that cytomegalovirus promotes the development and progression of gliomas; 2) """"""""Interferon-Mediated Suppression of MMP-9 Gene Expression and Function in Gliomas"""""""" which will examine the role of cytokines and signal transduction pathways in regulating secretion of a pro-invasive enzyme; 3) """"""""Ion Channels and Transporters as Novel, Glioma-specific Targets"""""""", which will examine how abnormal functioning of glioma ion channels can be potentially manipulated to develop new treatment modalities, 4) """"""""Viral and Molecular Chemotherapy of Malignant CNS Tumors"""""""", which will utilize the extensive expertise in virology available at UAB to development new gene and viral vector therapies for gliomas, and 5) """"""""The Role of TSP-1 and -2 in the Biology of Gliomas"""""""", which will investigate how to utilize fragments of the protein thrombospondin as anti-angiogenic agents. These projects will be supported by Four Cores: 1) Human Brain Tumor Tissue, 2) Clinical Trials; 3) Brain Tumor Animal Core Facility; and 4) Biostatistics. In addition, the SPORE will have a Career Development Program directed at developing the careers of young investigators in brain tumor translational research and a Developmental/Pilot Research Program. This SPORE has strong institutional commitments from both the University and its Cancer Center, and we fully expect to develop active collaborative interactions with both our institutional SPOREs as well as with other SPOREs nationally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097247-04
Application #
6919955
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M2))
Program Officer
Arnold, Julia T
Project Start
2002-09-05
Project End
2007-05-31
Budget Start
2005-06-08
Budget End
2006-05-31
Support Year
4
Fiscal Year
2005
Total Cost
$2,343,947
Indirect Cost
Name
University of Alabama Birmingham
Department
Neurology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Foreman, Paul M; Friedman, Gregory K; Cassady, Kevin A et al. (2017) Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics 14:333-344
Patel, Daxa M; Foreman, Paul M; Nabors, L Burt et al. (2016) Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev 27:69-78
Friedman, Gregory K; Moore, Blake P; Nan, Li et al. (2016) Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18:227-35
Jackson, Joshua D; Markert, James M; Li, Li et al. (2016) STAT1 and NF-?B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res 14:482-92
Friedman, Gregory K; Beierle, Elizabeth A; Gillespie, George Yancey et al. (2015) Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2:
Friedman, G K; Nan, L; Haas, M C et al. (2015) ??34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22:348-55
Cripe, Timothy P; Chen, Chun-Yu; Denton, Nicholas L et al. (2015) Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2:
Campbell, Susan L; Robel, Stefanie; Cuddapah, Vishnu A et al. (2015) GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia 63:23-36
Oliva, Claudia R; Markert, Tahireh; Gillespie, G Yancey et al. (2015) Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget 6:4330-44
Anderson, Joshua C; Taylor, Robert B; Fiveash, John B et al. (2015) KINOMIC ALTERATIONS IN ATYPICAL MENINGIOMA. Med Res Arch 2015:

Showing the most recent 10 out of 121 publications